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http:WHAT THIS PAPER ADDS
This study is the ﬁrst to look at the value of CTA plaque analysis in the lower limb. It was found that the burden
of calciﬁed plaque, but not soft or ﬁbrocalciﬁc plaque, is related to restenosis, reintervention, and Amputation-
Free Survival following endovascular treatment for femoropopliteal disease. CTA plaque analysis is accurate and
reproducible and may provide a novel tool when predicting outcome following endovascular intervention in the
lower limbs and guide our practice in procedure planning and surveillance.Introduction: Atherosclerotic plaque analysis using computed tomography angiography (CTA) has been found to
be accurate and reproducible in the coronary and carotid arteries. The aim of our study was to assess the utility of
this technique in predicting outcome following lower limb endovascular interventions.
Methods: Pre-procedural CTA was retrospectively analysed in 50 patients who had undergone femoropopliteal
(FeP) angioplasty (and/or stenting). Plaque analysis was performed using TeraRecon workstation by two
observers blinded to the long-term outcome. Using the Hounsﬁeld units (HU) scale atherosclerotic plaque
composition was subdivided into volumes of soft (e100e100 HU) ﬁbrocalciﬁc (101e300 HU) or calciﬁed (300e
1000 HU) components. The relationship between plaque composition, clinical and procedural variables, and the
study end points (vessel patency, binary restenosis rate, and Amputation-Free Survival [AFS]) were assessed using
multivariate analysis.
Results: The technical success rate of the endovascular procedure was 98%, with 48% of patients receiving FeP
stents. The AFS was 90%, primary patency 84%, assisted primary patency 88%, and binary restenosis 44% all at 1
year. A signiﬁcantly greater total volume of calciﬁed plaque (1.1 [.01e3.2] cm3 vs. .11 [0e1.86] cm3, p < .001)
was found in patients developing restenosis (>50%) compared with those who did not. Patients with a calciﬁed
plaque volume greater than 1.1 cm3 had a signiﬁcantly worse AFS than those with a volume less than 1.1 cm3
(p ¼ .0038). Multivariate analysis showed that the percentage calciﬁed plaque (p ¼ .003, HR 11.4, 95% CI 1.45e
37.29) was an independent predictor of binary restenosis at 12 months, and that absolute volume of calciﬁed
plaque (p ¼ .001, HR 3.56, 95% CI 1.64e7.7) was independently associated with AFS.
Conclusions: The burden of calciﬁed plaque, but not soft or ﬁbrocalciﬁc plaque is related to restenosis,
reintervention, and AFS. Computed tomography plaque analysis may form an important non-invasive tool for risk
stratiﬁcation in patients undergoing FeP endovascular procedures.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Computed tomography angiography (CTA) is a promising
technique in the evaluation of atherosclerotic plaque due to
its ability to provide structural images in multiple planes
with unique anatomical detail. Plaque elements can be
characterized by their CT attenuation proﬁles, with rupture-
prone coronary atherosclerotic plaques typically having a
large necrotic core and thin ﬁbrous cap.1,2 Differentiation of
these features is therefore critical for imaging modalities to
identify potentially high-risk plaques. In carotid arteries,
CTA has also been found to be extremely useful at deter-
mining degree of stenosis, ulceration, dissection, post-
radiation ﬁbrosis, calciﬁcation, and occlusion.3 CTA has
488 S.D. Patel et al.been used to create a plaque map, dividing the total area
into soft/necrotic, intermediate/ﬁbrous, and calciﬁed
areas.4e6 This technique has been validated against intra-
vascular ultrasound4,6 and histopathology5 and found to be
both accurate and reproducible.
Peripheral arterial disease can present as a spectrum of
disease from asymptomatic to ischaemic ulceration and
gangrene.7 Contrary to the situation in the coronary and
carotid arteries, plaque disruption and thrombosis is less
important than the degree of hemodynamic compromise
caused by atherosclerotic lesions. Different plaque charac-
teristics and composition may affect overall prognosis and
the response to endovascular intervention compared with
other arterial beds. A reliable non-invasive assessment of
plaque composition in the lower limb would constitute an
important step forward in developing a risk stratiﬁcation
tool, which may give information on likely disease pro-
gression and outcome following intervention. Recent ad-
vances in image analysis software have the potential to
improve the accuracy and reproducibility of CTA plaque
analysis, though these new techniques have yet to be
applied to the lower limb. There have also been rapid ad-
vances in stent technology, with many claiming to combat
vessel wall calciﬁcation and thus improve prognosis.8 Our
aim was to conduct a pilot study in order to test our hy-
pothesis that plaque composition detected on CTA plaque
analysis would be related to outcome following lower limb
endovascular interventions.METHODS
Patients
A prospectively collected angioplasty database was
screened for consecutive patients meeting the inclusion
criteria between 2011 and 2013 which included (a) patients
with incapacitating intermittent claudication or critical limb
ischaemia (Rutherford stage 3e6), (b) femoropopliteal (Fe
P) disease > 70% undergoing angioplasty (and/or stenting)
with or without concomitant infrapopliteal disease, (c) pre-
procedural CTA. Exclusion criteria were (a) intervention for
acute limb ischaemia, (b) previous FeP angioplasty or
stenting, or (c) FeP intervention proximal to a distal bypass,
(d) signiﬁcant aorto-iliac or common femoral stenosis. An
initial 64 patients met the inclusion criteria, and 14 were
subsequently excluded because they did not complete at
least 12 months of clinical and radiological follow-up.Imaging technique
It should be noted that CTAs were done only as part of
routine clinical care and not for the purposes of this study.
In our centre all patients have a duplex scan as the ﬁrst line
of investigation and will then have a second modality such
as a CTA or magnetic resonance angiography in order to
plan intervention, particularly in cases of advanced disease
which may require surgical intervention. CTA studies were
performed using a standardized protocol (Phillips Brilliance
64, Phillips, The Netherlands). All CTA studies wereperformed in helical scanning mode, with coverage
extending from the aortic bifurcation to the toes. Studies
were collimated at 0.625 mm, with a peak kilovoltage of
120, automated milliamps and a rotation time of 64  0.75
seconds. Approximately 100 mL of iodinated contrast was
administered via an intravenous cannulae at 4 mL/second
using a power injector.
Image analysis
Plaque analysis was performed using TeraRecon 3D work-
station (Aquarius iNtuition Viewer, Aquarius, TeraRecon, San
Matteo, CA, USA; Fig. 1) by two investigators blinded to the
long-term outcome. CTAs were reconstructed in the
straightened multiplanar reformatting mode (sMPR) with
manual centerline. The FeP section which underwent
intervention was then isolated (termed region of interest[
ROI] Fig. 1A) by referring back to the intraprocedural
angiographic images. The “plaque analysis” module on
TeraRecon was then used to delineate the inner and outer
walls of the vessel (including the plaque) from surrounding
tissue and lumen (Fig. 1B,C). This was then checked and
manually corrected by the investigators. A set of Hounsﬁeld
unit (HU) intensity ranges were then deﬁned and mapped
to a colour overlay to visualize various elements of a lesion
(Fig. 1C). The volume of each deﬁned tissue category was
then automatically calculated by the programme within the
ROI. In addition, the programme also calculates the total
vessel volume, lumen volume, and volume “in-between”
within the ROI. The HU intensity ranges selected were based
on previous reports4,5 and the programme speciﬁcation
(Table 1). Interobserver and intraobserver variability was
analysed using the intraclass correlation coefﬁcient (ICC).
The interobserver correlation (10 CTAs analysed by two
investigators) was 0.93 (95% CI 0.83e0.95) and intra-
observer correlation (10 CTAs analysed by the same
observer twice) was 0.91 (95% CI 0.85e0.97). Therefore,
subsequent CTA plaque analysis was done by one examiner
only. Analysis was performed on the volume of each type of
plaque in the ROI (plaque volume) and on the percentage of
each type of plaque calculated as a volume of each type
divided by the total plaque volume in the ROI (plaque
percentage).
Clinical follow-up
All patients underwent routine clinical follow-up including
outpatient appointments at 3 and 6 months. In addition,
our centre has a duplex surveillance protocol for all angio-
plasties that includes a scan at 3 months and thereafter as
clinically indicated. The data from all patients were retro-
spectively collected and recorded in a computerised data-
base incorporating multiple variables such as preoperative
demographics, procedure-related variables, and anatomical
factors. The study end points were target vessel primary
patency, primary assisted patency, secondary patency, bi-
nary restenosis rate, and Amputation-Free Survival (AFS) at
12 months using KaplaneMeier analysis and deﬁned ac-
cording to the published Society for Vascular Surgery
Figure 1. Computed tomography angiography plaque analysis. (A) Multiplanar reformat with centerline and region of interest identiﬁed.
(B) Transverse section with lumen identiﬁed. (C) Outer wall line and plaque colour map with soft (red), ﬁbrocalciﬁc (green), and calciﬁed
(blue) components.
Atherosclerotic Plaque Analysis: A Pilot Study 489reporting standards.9 These data were collected by in-
vestigators blinded to the CT plaque analysis scores.
Statistical analysis and sample size
Continuous variables are expressed as mean  standard
deviation (SD) for parametrically distributed data and me-
dian (range) for non-parametric data, whereas categorical
variables are presented as absolute values and percentages.
Differences between continuous variables were analysed by
the unpaired Student t test or the ManneWhitney U test,
and those between categorical variables by the chi-square
test as appropriate. KaplaneMeier analysis was used to
calculate the primary end points and to compare curves
using the log rank test. The relationship between plaque
composition, clinical and procedural variables, and binary
restenosis at 1 year was analysed using binary logistic
regression analysis and AFS using a Cox regression model. A
p value < .05 was considered statistically signiﬁcant. All
analyses were carried out using SPSS 19 (IBM, New York,
USA). A prospective sample size calculation was not
possible due to a lack of published data. A retrospective
power calculation based on the mean values of calciﬁed
plaque, the standard deviation, and the population of 11
patients who suffered an event (amputation or death)
showed a power of 72% to detect a difference in AFS.Table 1. Hounsﬁeld unit ranges for plaque component separation.
Plaque component Hounsﬁeld unit range
Soft 100e100
Fibrocalciﬁc 101e300
Calciﬁed >300RESULTS
Patient characteristics
We analysed a total of 50 patients undergoing FeP an-
gioplasty, with demographic and cardiovascular risk factor
proﬁles shown in Table 2. Preoperative medication
included aspirin (n ¼ 34, 68%), clopidogrel (n ¼ 8, 16%),
warfarin (n ¼ 9, 18%), a statin (n ¼ 44, 88%), and beta-
blockers (n ¼ 13, 26%) with only seven (14%) patients
on neither anticoagulants nor antiplatelets. These latter
patients had a loading dose of aspirin intraoperatively with
a maintenance dose continued postoperatively. Indications
for treatment were Rutherford classiﬁcation 3 (n ¼ 8,
16%), 4 (n ¼ 22, 44%), or 5 (n ¼ 20, 40%) peripheral
arterial disease.
Procedural details
Mean pre-procedural FeP stenosis was 83  11%, iliac
stenosis was 12  14%, and the median number of patent
tibial run-off vessels was two (range 1e3). Disease severity
was classiﬁed as TASC II B in four (8%); C in 32 (64%); and D
in 14 (28%). The median length of treated artery was 278
(43e330) mm, with 26 patients receiving stents. Patients
that experienced periprocedural ﬂow-limiting dissections
had a bare metal stent (BMS) inserted (n ¼ 4). In cases of
immediate arterial recoil BMS (n ¼ 8) or drug eluting stents
(DES, n ¼ 10) were used according to operator preference,
and covered stents used only where there was signiﬁcant
extravasation of contrast indicating vessel rupture (n ¼ 4).
The technical success rate was 98% and limb salvage at 1
year was 94%, with three amputations at a median of 3 (1e
Table 2. Univariate analysis of factors affecting restenosis at 1 year.
Univariate analysis Restenosis <50%, n ¼ 27(%) Restenosis> 50%, n ¼ 23 p
Demographic Age (mean  SD) 75 (10) 74 (11) .9
Sex (M:F) 16:11 16:7 .56
IHD (%) 9 (33) 9 (39) .77
Previous stoke/TIA (%) 4 (15) 6 (26) .48
DM (%) 9 (33) 14 (61) .04
Smoker (%) 3 (11) 5 (22) .07
Hypertension (%) 20 (74) 12 (52) .14
Hypercholesterolaemia (%) 11 (41) 9 (39) .9
Creatinine (mmol/L) 91 (50) 78 (29) .3
eGFR (mL/min/1.73m2) 74 (26) 92 (41) .02
Medication Aspirin 18 (67) 16 (70) .5
Clopidogrel 4 (15) 4 (17) .5
Statin 22 (81) 22 (96) .19
Beta-blocker 5 (19) 8 (35) .2
Procedure FeP stenosis 92 (10) 88 (9) .17
Length of angioplasty (ROI) 231 (83) 256 (69) .43
Stent insertion 16 (59) 10 (43) .39
Subintimal angioplasty 13 (48) 7 (30) .25
Plaque volume (cm3) Soft 7.4(1.2e30) 5.5(1e33) .26
Fibrocalciﬁc 1.7 (0.16e4.7) 2 (0.34e7.34) .14
Calciﬁed 0.11 (0e1.86) 1.1 (0.01e3.2) .0004
% plaque Soft 75 (41e99) 59 (35e95) .01
Fibrocalciﬁc 18 (1e47) 24 (4e37) .21
Calciﬁed 1.9 (0e13) 9.6 (0e35) .0002
IHD: ischaemic heart disease; DM: diabetes mellitus; CRF: chronic renal failure; TIA: transient ischaemic attack.
Table 3. Factors associated with worse Amputation-Free Survival
by log rank test.
Variable p
490 S.D. Patel et al.5) months. The AFS was 90%, primary patency 84%, assisted
primary patency 88% (Fig. 2), and binary restenosis (>50%)
44% all at 1 year by KaplaneMeier analysis. Ten patients
had target lesion revascularisation (9 angioplasty and
stenting, 1 surgical bypass), and a further four patients had
angioplasty of the below-knee vessels at a median of 7 (1e
27) months.
Plaque analysis
The median arterial wall volume on CTA within the ROI
(treated length of artery) was 10.4 (1.57e43.90) cm3. Pla-
que analysis showed this to be composed of a median 5.7
(1.04e33.0) cm3 of soft plaque, 1.83 (0.16e7.3) cm3 of
ﬁbrocalciﬁc plaque and 0.42 (0e3.2) cm3 of calciﬁed plaque.
A signiﬁcantly greater total volume of calciﬁed plaque (1.10 4 8 12 16 20 24 28
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Figure 2. Primary patency and primary assisted patency by
KaplaneMeier analysis (interrupted line denotes standard error for
each curve.[0.01e3.2] cm3 vs. 0.11 [0e1.86] cm3, p < .001, Table 2)
was found in patients developing restenosis >50% (n ¼ 23)
compared with those who did not (n ¼ 27). The volume of
soft and ﬁbrocalciﬁc plaque was not signiﬁcantly different in
the two groups. Analysis by percentage of plaque volume
showed that those developing restenosis had a signiﬁcantly
smaller percentage of soft plaque (59 [35e95] vs. 75 [41e
99], p ¼ .01) and a greater percentage of calciﬁed plaque
(9.6 [0e35] vs. 1.9 [0e13] p ¼ .0002, Table 3) than those
who did not develop restenosis. In addition to plaque
composition, other factors signiﬁcantly associated withDemographic Male sex .16
IHD .58
Previous stoke/TIA .41
DM .52
Smoker .12
Hypertension .27
Hypercholesterolaemia .9
Medication Aspirin .003
Clopidogrel .86
Statin .65
Beta-blocker .06
Procedural variable Stent insertion .93
Subintimal angioplasty .35
Plaque composition Calciﬁed plaque volume >1.1 cm3 .004
% Calciﬁed plaque >9.6% .013
IHD: ischaemic heart disease; DM: diabetes mellitus; CRF: chronic
renal failure; TIA: transient ischaemic attack.
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Figure 3. Amputation-Free Survival (AFS) by KaplaneMeier anal-
ysis in patients with <1.1 cm3 vs.  1.1 cm3 calciﬁed plaque
volume (n ¼ 36 and 14 respectively; interrupted line denotes
standard error for each curve).
Atherosclerotic Plaque Analysis: A Pilot Study 491restonosis (>50% at 1 year) on univariate analysis were
diabetes mellitus (p ¼ .04) and a higher estimated
glomerular ﬁltration rate (p ¼ .02, Table 2).
Total calciﬁed plaque volume was signiﬁcantly lower in
patients remaining free from FeP occlusions or reinter-
ventions (0.21 [0.01e2.6] cm3 vs. 1.05 [0e3.2] cm3, n ¼ 32
vs. 18, p ¼ .01), whereas soft (5.6 [1.2e25] cm3 vs. 7.5(1e
33), p ¼ .44) and ﬁbrocalciﬁc (1.77 [0.16e4.7] vs. 2 [0.18e
7.34], p ¼ .31) plaque volume were similar. Taking a cut-off
value of 1.1 cm3 of calciﬁed plaque volume (median value
of patients developing > 50% restenosis; Table 2), we found
that AFS was signiﬁcantly worse in those with a
volume  1.1 cm3 compared with <1.1 cm3 (p ¼ .0038, log
rank test; Fig. 3). Likewise AFS was signiﬁcantly worse in
patients with a percentage of calciﬁed plaque >9.6%
(p ¼ .013) and in patients who were not on aspirin before
the procedure (p ¼ .003, Log rank test; Table 3).
There was a positive correlation between the degree of
FeP stenosis and the volume of soft plaque (R ¼ .44,
p ¼ .001) but not ﬁbrocalciﬁc (R ¼ .13, p ¼ .35) or
calciﬁed plaque (R ¼ .18, p ¼ .19). There was also a
positive correlation between the length of the ROI and total
volume of soft (R ¼ .34, p ¼ .017), ﬁbrocalciﬁc (R ¼ .55,
p < .001), and calciﬁed plaque (R ¼ .29, p ¼ .04). Multi-
variate analysis was performed to adjust for these and other
confounding factors such as patient comorbidities and
procedural variables that were found to be positive in theTable 4. Multivariate analysis of factors predicting restonsis at 1 year
End point Variable
Binary restenosis
(binary logistic regression)
DM
eGFR
ROI
Volume calciﬁed plaque
% Soft plaque
% Calciﬁed plaque
Ampuation-free survival
(Cox regression model)
Age
eGFR
Aspirin
ROI
Volume of Calciﬁed plaque
% Calciﬁed plaque
eGFR: estimated glomerular ﬁltration rate; ROI: region of interest.univariate analysis (Tables 2 and 3). Binary logistic regres-
sion analysis (Table 4) showed that the percentage of
calciﬁed plaque (p ¼ .003, HR 11.4, 95% CI 1.45e37.29) was
an independent predictor of binary restenosis at 12 months,
whereas the absolute volume of calciﬁed plaque was not
(p ¼ .73). Cox regression analysis (Table 4) showed that
absolute volume of calciﬁed plaque (p ¼ .001, HR 3.56, 95%
CI 1.64e7.7) was inversely associated with AFS whereas the
percentage of calciﬁed plaque was not (p ¼ .064). In
addition, taking aspirin preprocedurally was found to be
independently associated with better AFS (p ¼ .004, HR
27.4, 95% CI 3.02e242.3). No other factors were found to
be signiﬁcantly associated with restenosis or AFS on
multivariate analysis.
DISCUSSION
Our data suggest that CTA plaque analysis in lower limb Fe
P lesions correlates with outcome following endovascular
intervention. We found a strong association between the
percentage of calciﬁed and binary restenosis rate and a
negative correlation of total volume of calciﬁed plaque and
AFS. Of note, the volume and percentage of soft and in-
termediate plaque does not appear to be as important to
the outcome, which is contrary to the ﬁndings in the cor-
onary and carotid arterial beds, and conﬁrms our hypoth-
esis that calciﬁc plaque components can be of prognostic
value following lower limb interventions.
The accuracy of CTA in differentiating between different
plaque components using their HU attenuation proﬁles has
been established in the carotid and coronary arteries,
although no studies were found looking at CTA plaque
analysis in the lower limb using this technique. In a study
involving 45 patients with acute coronary syndrome (ACS)
and using intravascular ultrasound (IVUS) as the gold stan-
dard, these authors demonstrated sensitivities of 92%, 87%,
and 89% for detection of soft, intermediate, and calciﬁed
plaques, respectively, and compared with angioscopy,
sensitivity was 80% and speciﬁcity was 87%.4 CTA cross-
sections obtained at intervals of 5 mm were converted to
numerical data and a “plaque map” was drawn using a
colour-based isometric line method based on HU. This studyand Amputation-Free Survival.
Hazard ration 95% CI p
0.27 0.05e1.45 .129
1.03 1e1.06 .065
1.00 0.99e1.01 .359
1.37 .22e8.4 .731
7.62 0.06e14.1 .480
11.4 1.45e37.2 .003
1.042 1.28e19.31 .487
1.055 1.0e1.04 .074
27.4 3.02e242.3 .004
1.015 0.99e1.03 .151
3.56 1.64e7.7 .001
0.23 1.12e13.21 .064
492 S.D. Patel et al.used an automated system to then work out the volumes of
the different plaque components, which is similar to our
method.
Another study attempted to correlate CTA imaging ﬁnd-
ings with histological ﬁndings in an effort to establish if it
could be used to identify vulnerable carotid plaques.10 The
correlation for plaque calciﬁcation, large lipid cores, large
haemorrhages, ulcerations, and ﬁbrous cap thickness was
very good. The ability of CTA to identify a lipid-rich necrotic
core, connective tissue, and haemorrhage was much more
limited. This study relied on manual analysis and correlation
of CTA and histological images, and the authors acknowl-
edge that this is potential source of bias. The methodology
used in this paper is dependent on accurate isolation of the
ROI and then corroboration and minor adjustment of the
lumen and outer wall lines. Once these are in place, the
remaining process is fully automated leaving little room for
bias or observer error as demonstrated by the high inter-
and intraobserver correlation in this study. Some authors
have raised doubts about the value of HU in distinguishing
between speciﬁc plaque elements.11,12 However, the last
two studies11,12 used average HU per axial image rather
than trying to distinguish a plaque proﬁle within each axial
section and therefore the results are not directly compa-
rable with this study. Two other studies have highlighted
differences for the discrimination between calciﬁed and
non-calciﬁed plaques,13,14 although both studies showed
high sensitivities (94e95%) and speciﬁcities (92e94%) for
detection of calciﬁed plaques.
Within studies using similar methodology to this one,
there is some variation in the exact deﬁnition of soft,
ﬁbrous/intermediate, and calciﬁed plaque by HU. In carotid
plaques, a density of less than 50 HU was classiﬁed as fatty
plaque, mixed plaque (50e119 HU), and calciﬁed plaque
(>120 HU).15 In a study of coronary plaques, soft plaques
had a density of 14  26 HU (range 42 to þ47 HU), in-
termediate plaques of 91  21 HU (61e112 HU) and
calciﬁed plaques of 419  194 HU (126e736 HU).6 Others
have deﬁned soft, intermediate, and calciﬁed plaque as
having a proﬁle curve < 50 HU, 50e150 HU, and >500 HU,
respectively.4 Although the difference between these
studies is small, the last two studies are broadly in agree-
ment and after consultation with the manufacturers of the
plaque analysis software, we used ranges of 100e100 HU,
101e300 HU, and >300 HU for soft, ﬁbrocalciﬁc, and
calciﬁed plaque respectively.
Compared with carotid ultrasound, CTA appears to have
better inter-rater reliability and to be less dependent on the
observer.16 Duplex ultrasound also becomes less reliable
with more calciﬁed vessels, and this is particularly of
concern in the lower limb arteries of patients with diabetes
and renal failure. There is much work particularly in the
carotid and coronary vascular beds on magnetic resonance
imaging (MRI)-based plaque analysis. However, the wide-
spread use of this imaging modality as a risk stratiﬁcation
tool in the clinical setting is limited by the need for special
MRI coils, lengthy acquisition times, and the complexity of
image interpretation. On the other hand, CT is associatedwith a higher radiation dose, and administration of contrast
medium is also required with the associated risks of
nephrotoxicity and anaphylaxis.
CTA plaque analysis has been shown to correlate with
clinical end-points. In patients presenting with acute chest
pain, high-risk plaque detected on coronary CTA can predict
acute coronary syndrome independent of the degree of
stenosis and cardiovascular risk factors.17 In patients with
high-grade carotid stenosis, symptomatic patients had
signiﬁcantly larger soft plaque and total plaque thickness
and smaller hard plaque thickness on CTA. Each 1-mm in-
crease in soft plaque resulted in approximately three times
greater odds of previous stroke or transient ischaemic
attack.18 It has been shown that restenosis was associated
with a signiﬁcantly higher percentage of calciﬁed plaque but
not absolute calciﬁed plaque volume. The restenosis rate is
an outcome that is conﬁned to the area of intervention and
this may explain its greater association with the percentage
of calciﬁed plaque, a relative measure that corrects for
lesion length, and not to general atherosclerotic plaque
burden. Conversely, a higher absolute volume of calciﬁed
plaque was associated with a signiﬁcantly lower AFS,
reﬂecting the impact of widespread atherosclerosis and its
effect on overall survival and the severity of peripheral
vascular disease. These results can have a direct impact on
both clinical care and decision-making, thereby potentially
offsetting the cost and risk of CTA. It should also be noted
that CTAs are done commonly by many surgeons in order to
plan revascularisation, and therefore in most patients there
would be no additional risk or cost and indeed plaque
analysis would be an added beneﬁt. A high burden of
calciﬁed plaque detected on pre-procedural CTA could
provide an objective measure which may guide treatment
strategy such as subintimal angioplasty, stent insertion, or
an alternative strategy such as the use of an atherectomy
device. These patients may also be chosen for closer sur-
veillance during the follow-up period whereas those with
lower calciﬁed plaque volumes, and therefore lower risk of
restenosis, may not require surveillance as frequently. This
has an impact on health care planning and resource allo-
cation. Finally, the knowledge that CTA plaque analysis
correlates with clinically detectable outcome measures can
also guide informed discussion with patients.
This is a small pilot study and as such is subject to a
number of confounding factors. The most important of
these is the impact of arterial stenting on plaque recoil and
restenosis. The decision to place a stent was a subjective
one made at the time of the procedure. In addition, disease
severity and distribution and patient comorbidities are also
confounding factors in our analysis and it can be argued
that calciﬁed plaque volume is a surrogate marker for these
variables. We have attempted to compensate for these
confounding factors by undertaking a multivariate analysis
which conﬁrmed calciﬁed plaque volume and percentage of
calciﬁed plaque to be independent factors affecting AFS and
restenosis respectively.
The binary restenosis rate of 44% at 1 year was higher
than expected, but is similar to other studies of FeP
Atherosclerotic Plaque Analysis: A Pilot Study 493stenting,19 especially when considering that largely TASC II
C and D lesions were treated. The pilot study looked at only
50 patients with FeP stenosis, and it is fully acknowledged
that many patients have multilevel disease. Further pro-
spective studies in larger patient cohorts are needed to
validate the present data, and in particular in patients with
multilevel disease. Finally, corroboration of CTA plaque
analysis with IVUS or histology has not been undertaken.
This decision was made on the strength of the published
data as outlined above, which showed that, in the carotid
and coronary vascular beds, CTA was sensitive and speciﬁc
at discriminating different plaque morphology.
In conclusion, it was found that the burden of calciﬁed
plaque (>300 HU), but not soft (100e100 HU) or ﬁbro-
calciﬁc (101e300 HU) plaque is related to restenosis, rein-
tervention, and AFS. CTA plaque analysis is accurate and
reproducible and may provide a novel non-invasive tool
when predicting outcome following endovascular inter-
vention in the lower limbs and guide practice in procedure
planning and surveillance, as well as helping to decide be-
tween open and endovascular revascularisation.
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